Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...

died in the imipenem/cilastatin group. This study prompted the FDA to issue a warning in September this year for the increased mortality associated with tigecycline in patients with severe infections.

Review the side-effects of Imipenem and Cilastatin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication.

Hence, faropenem should be started at low doses of 150 mg in the elderly and patients should be monitored for adverse effects like loose bowel movements and diarrhea • When taken with imipenem ...

The term "alert and oriented" (AO) is a medical notation describing a person's level of consciousness and cognition (the ability to understand and learn through thought, experiences, and the senses).

The Phase III PIVOT-PO trial (NCT06059846) will compare oral tebipenem HBr with the two carbapenem antibiotics combination, intravenous imipenem and cilastatin, in hospitalised adult patients with ...

This randomized, double-blinded trial compares oral tebipenem HBr with intravenous imipenem cilastatin, in hospitalized adult patients with cUTI/AP. The primary endpoint is overall response (a ...

Enrollment on track in PIVOT-PO, the global Phase 3 clinical trial of tebipenem HBr in patients with cUTI. This randomized, double-blinded trial compares oral tebipenem HBr with intravenous imipenem ...